Clinical Trial Update: KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating KD6001 in combination with an anti-PD-1 antibody for advanced melanoma is underway, with no status reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-PD-1 antibody
• KD6001

Snippet

Sponsor: Shanghai Kanda Biotechnology Co., Ltd. | Conditions: Melanoma | Phase 1, Phase 2 | Status: UNKNOWN